C-Ray Therapeutics Deal History & Licensing Activity
C-Ray Therapeutics is a life sciences. Over the past three years, C-Ray Therapeutics has been involved in 1 licensing and acquisition transaction, with a primary focus on Radiopharmaceuticals (2 deals). The company currently has 1 active clinical trial, primarily in Oncology.
Deals (12mo)
2
Active Trials
1
Top Modality
Radiopharmaceuticals
Focus Area
Oncology
C-Ray Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving C-Ray Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| no-carrier-added lutetium-177 (n.c.a. Lu-177) | SHINE Technologies, LLC | Radiopharmaceuticals | Approved | license | Mar 2026 |
C-Ray Therapeutics Pipeline Focus
Therapeutic areas and modalities where C-Ray Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
C-Ray Therapeutics Clinical Pipeline
C-Ray Therapeutics has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches C-Ray Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About C-Ray Therapeutics Licensing & Deal Activity
C-Ray Therapeutics is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, C-Ray Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for C-Ray Therapeutics include Oncology (2 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, C-Ray Therapeutics has shown particular interest in radiopharmaceuticals.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for C-Ray Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against C-Ray Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.